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Background. Electrochemotherapy is a tumour ablation modality, based on electroporation of the cell membrane, 
allowing non-permeant anticancer drugs to enter the cell, thus augmenting their cytotoxicity by orders of magnitude. 
In preclinical studies, bleomycin and cisplatin proved to be the most suitable for clinical use. Intravenous administra-
tion of cisplatin for electrochemotherapy is still not widely accepted in the clinics, presumably due to its lower antitu-
mor effectiveness, but adjuvant therapy by immunomodulatory or vascular-targeting agents could provide a way for 
its potentiation. Hence, the aim of the present study was to explore the possibility of adjuvant tumour necrosis factor 
α (TNF-α) therapy to potentiate antitumor effectiveness of electrochemotherapy with intravenous cisplatin administra-
tion in murine sarcoma.
Materials and methods. In vivo study was designed to evaluate the effect of TNF-α applied before or after the elec-
trochemotherapy and to evaluate the effect of adjuvant TNF-α on electrochemotherapy with different cisplatin doses.
Results. A synergistic interaction between TNF-α and electrochemotherapy was observed. Administration of TNF-α 
before the electrochemotherapy resulted in longer tumour growth delay and increased tumour curability, and was 
significantly more effective than TNF-α administration after the electrochemotherapy. Tumour analysis revealed 
increased platinum content in tumours, TNF-α induced blood vessel damage and increased tumour necrosis after 
combination of TNF-α and electrochemotherapy, indicating an anti-vascular action of TNF-α. In addition, immu-
nomodulatory effect might have contributed to curability rate of the tumours. 
Conclusion. Adjuvant intratumoural TNF-α therapy synergistically contributes to electrochemotherapy with intrave-
nous cisplatin administration. Due to its potentiation at all doses of cisplatin, the combined treatment is predicted to 
be effective also in tumours, where the drug concentration is suboptimal or in bigger tumours, where electrochemo-
therapy with intravenous cisplatin is not expected to be sufficiently effective. 
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Introduction
Electrochemotherapy is a non-thermal tumour 
ablation modality that is safe and effective in any 
solid tumour type. Electrochemotherapy is based 
on the local delivery of electric pulses that permea-
bilize the cell membrane, allowing non-permeant 
or low-permeant anticancer drugs to enter the cell, 
thus augmenting their cytotoxicity by orders of 
magnitude. Treatment is safe, very well tolerated 
by the patients, and its efficacy is very high on the 
different tumour nodules.1 Electrochemotherapy 
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has gained a role in routine clinical practice for 
treatment of cutaneous and subcutaneous tumours 
as local therapy.2,3 The development of specialized 
electrodes has made it possible to apply electro-
chemotherapy also to deep-seated tumours.4,5 The 
results of the first preclinical and clinical studies 
using specialized electrodes demonstrated feasibil-
ity of this approach for treatment of deep-seated 
tumours in liver and brain as well as for bone tu-
mours and metastases.4,6-11
Among the drugs that have been tested in pre-
clinical studies, bleomycin and cisplatin (CDDP) 
proved to be the most suitable for clinical use of 
electrochemotherapy. In the clinical use, both can 
be administered locally in the tumour, but only 
bleomycin systemically, intravenously, to obtain 
pronounced antitumor effect. Namely, in preclini-
cal studies it was demonstrated that intratumoural 
administration of CDDP is more effective than 
systemic administration.12-14 The mechanisms of 
antitumor action of electrochemotherapy using 
both drugs are multifactorial, including anti-vas-
cular effect and immune response stimulation.15,16 
The activation of immune response is presum-
ably due to the direct cytotoxic effect on tumour 
cells leading to immunological cell death.16 Hence, 
to potentiate antitumor effectiveness of systemic 
electrochemotherapy, we explored the possibility 
of additional intratumoural application of recom-
binant tumour necrosis factor α (TNF-α). TNF-α 
is a well-known pro-inflammatory cytokine with 
a wide range of biological functions.17 In addi-
tion to its immunomodulatory role, it also has an 
anti-vascular effect.18 To extend the application of 
electrochemotherapy with intravenous CDDP ad-
ministration, addition of TNF-α could enhance the 
antitumour effectiveness of electrochemotherapy 
through its biological functions. Therefore, the aim 
of the present study was to explore the possibility 
of adjuvant intratumoural TNF-α therapy to elec-
trochemotherapy with intravenous CDDP admin-
istration in murine sarcoma.
Materials and methods
Cell line
Murine fibrosarcoma cell line SA-1 (The Jackson 
Laboratory, Bar Harbor, ME, USA) was grown as 
monolayer in Eagle Minimum Essential Medium 
(EMEM) with Glutamax (Invitrogen, Paisley, 
UK), supplemented with 10% foetal calf serum 
(FCS) (Invitrogen) and gentamicin (30 μg/mL) 
(Invitrogen). Cells were routinely subcultured 
twice a week and incubated in an atmosphere with 
5% CO2 at 37°C.
Drug
CDDP (Medac, Wedel, Germany) was dissolved in 
sterile H2O. For each experiment, a fresh solution 
of CDDP was prepared. In vitro, the final concen-
trations of CDDP were prepared in EMEM. CDDP 
concentrations of 0.1 μg/mL and 0.5 μg/mL were 
used in the in vitro experiments.
Murine recombinant TNF-α was obtained from 
Affymetrix eBioscience (Santa Clara, CA, USA). 
The final concentrations of TNF-α were prepared 
in phosphate buffered saline (PBS) (Invitrogen). 
TNF-α concentrations 2.5x103 U/mL, 2.5x104 U/mL, 
and 2.5x105 U/mL were used in the in vitro experi-
ments. 
In vitro electroporation
Confluent cell cultures were trypsinized, washed in 
EMEM with FCS for trypsin inactivation and once 
in electroporation buffer (125 mM sacharose; 10 
mM K2HPO4; 2.5 mM KH2PO4; 2 mM MgCl2·6H20) 
at 4°C. The final cell suspension (22 x 106 cells/mL) 
was prepared in electroporation buffer at 4°C. Cells 
(2 x 106) were mixed with CDDP and/or TNF-α. 
Half of this mixture (1 x 106 cells) was placed be-
tween two parallel stainless steel electrodes with a 
2 mm gap in-between and subjected to eight square 
wave electric pulses (EP) with voltage to distance 
ratio 1300 V/cm, pulse duration 100 μs and fre-
quency 1 Hz. EP were generated by generator of 
EP ELECTRO CELL B10 (Betatech, Saint-Orens-
de-Gameville, France). The other half of the mix-
ture served as a control for CDDP and/or TNF-α 
treatment alone. After electroporation, cells were 
incubated at room temperature for 5 min, diluted 
in 2 mL of growth medium and then plated for the 
clonogenic assay.
Clonogenic assay
Sensitivity of SA-1 cells exposed to CDDP or 
TNF-α alone, a combination of CDDP and TNF-α, 
EP alone, electrochemotherapy with CDDP (ECT), 
EP + TNF-α and ECT + TNF-α was determined by 
clonogenic assay. SA-1 cells were plated at a con-
centration of 200 cells/dish for exposure to CDDP 
or TNF-α alone and 500 cells/dish for combination 
of electroporation and CDDP or TNF-α. After 7 
days colonies were fixed, stained with crystal vio-
let and counted. The survival curve for the electro-
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chemotherapy-treated cells was normalised for the 
cytotoxicity of EP treatment alone. The experiment 
was repeated twice in triplicates.  
Tumour and animal model
Murine fibrosarcoma SA-1 cells syngeneic to A/J 
mice (Harlan, Udine, Italy) were used in the study. 
Mice were maintained in a specific pathogen-free 
animal colony at constant room temperature (20-
24°C), relative humidity (55±10%), and 12 hour 
light/dark cycle. Food and water were provided ad 
libitum. Animals were subjected to an adaptation 
period of 7-10 days before the experiments were 
carried out. All procedures on animals were per-
formed in accordance with the official guidelines of 
European Union Directive 2010/63/EU and with the 
permission of the Ministry of Agriculture and the 
Environment of the Republic of Slovenia (permis-
sion no. 34401-4/2012/2) which was granted based 
on the approval of Ethical committee for animal 
experimentation of the Republic of Slovenia. At the 
beginning of the experiment, the animals were 9-11 
weeks old. Solid tumours were induced by subcuta-
neous injections of SA-1 cells (5·105 cells/0.1 mL 0.9% 
w/v NaCl) in the right flank prepared from the as-
cites from donor mouse. When the tumours reached 
approximately 40 mm3 in volume, the animals were 
randomly divided into experimental groups and 
subjected to a specific experimental protocol.
In vivo electroporation
EP were delivered by generator of EP ELECTRO 
CELL B10 using flat parallel electrodes with 8 mm 
gap. Electrodes were placed percutaneously at the 
opposite tumour margins. Electroporation of tu-
mours was performed by applying eight square-
wave EP with voltage to distance ratio 1300 V/cm, 
pulse width 100 μs and repetition frequency 1 Hz 
with a perpendicular change of electrode orienta-
tion after 4 pulses. Good contact between the elec-
trodes and the overlying skin was ensured by con-
ductive gel (Parker Laboratories, Fairfield, NJ, USA). 
In vivo study design
To evaluate the influence of TNF-α on the antitu-
mour effectiveness of electrochemotherapy, TNF-α 
(1 x 105 U) was applied intratumourally (i.t.) ei-
ther 5 min before or after the application of EP. 
CDDP (4 mg/kg) was injected intravenously (i.v.) 
3 min before the application of the electric pulses 
(Figure 1). The pertinent groups were control 
(untreated tumours), EP (application of EP only), 
CDDP (injection of CDDP only), TNF-α (injection 
of TNF-α only), ECT (electrochemotherapy with 
CDDP), EP + TNF-α -5 min (injection of TNF-α 5 
min before the application of EP), EP + TNF-α +5 
min (injection of TNF-α 5 min after the application 
of EP), CDDP + TNF-α -2 min (injection of TNF-α 2 
min before the injection of CDDP), CDDP + TNF-α 
+8 min (injection of TNF-α 8 min after the injection 
of CDDP), ECT + TNF-α -5 min (injection of TNF-α 
5 min before electrochemotherapy), and ECT + 
TNF-α +5 min (injection of TNF-α 5 min after elec-
trochemotherapy).
In the second part of the in vivo study, the anti-
tumour effect of TNF-α in combination with elec-
trochemotherapy with different CDDP doses was 
evaluated. TNF-α was injected 2 min before the 
injection of CDDP (dose range 1 – 8 mg/kg) and 5 
min before the application of electric pulses. 
After the therapy, tumour growth was followed 
up by measurements of tumour diameters with a 
digital calliper. Tumour volume was calculated by 
the formula V=a·b·c·π/6, where a, b and c were three 
mutually orthogonal tumour diameters. From the 
calculated volume, arithmetic means and stand-
ard error of the means were calculated for each 
experimental group. Tumour doubling time was 
determined for each individual tumour, and tu-
mour growth delay was calculated from the mean 
doubling time of experimental groups. When the 
tumour volume reached 300 mm3, animals were 
considered incurable and were humanely eutha-
nized. When the tumours became impalpable, the 
response to treatment was scored as complete re-
sponse. Mice that were in complete response 100 
days after the treatment were considered as cured. 
In addition, the weight of the mice was followed as 
a general toxicity index.
Determination of platinum content in 
tumours after treatment 
Mice were sacrificed 24 h after treatment with CDDP 
(4 mg/kg), electrochemotherapy, combination of 
TNF-α and CDDP, and combination of TNF-α and 
electrochemotherapy. Tumours were excised and 
Figure 1. Time schedule of the treatment.
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removed from the overlying skin. To determine 
platinum content in tumours after treatment, tu-
mours were weighed, placed in 15-mL graduated 
polyethylene tubes and digested in 0.5 mL 65% ni-
tric acid by incubation at 37°C for 2 days to obtain 
a clear solution. Platinum content in the samples 
was determined by electrothermal atomic absorp-
tion spectrometry on a Hitachi Z-8270 Polarized 
Zeeman Atomic Absorption Spectrometer, adjusted 
to a wavelength of 265.9 nm. 
Tumour histology 
Mice were sacrificed 24 h after treatment with 
CDDP, electrochemotherapy, combination of 
TNF-α and CDDP, and combination of TNF-α and 
electrochemotherapy. Tumours were excised, re-
moved from the overlying skin and fixed in IHC 
zinc fixative (BD Pharmingen, BD Biosciences, San 
Diego, CA, USA) for 24 h at room temperature, and 
embedded in paraffin. Two series of 2 μm thick tis-
sue sections were cut from each paraffin block with 
step thickens of 20 μm.
First series of tissue sections were used for im-
munohistochemical staining of CD31, a marker 
for endothelial cells. Sections were incubated 
with rabbit polyclonal antibodies against murine 
CD31 (ab28364, Abcam, Cambridge, MA, USA) at 
dilution 1:1000. A peroxidase-conjugated strepta-
vidin–biotin system (Rabbit specific HRP/DAB 
detection IHC kit, ab64261, Abcam) was used as 
the colorogenic reagent followed by haematoxy-
lin counterstaining. The immunohistochemically 
stained sections were examined in blind fashion 
under light microscopy and 5 images of viable tu-
mour tissue from the same tumour section were 
captured with a DP72 CCD camera (Olympus, 
Hamburg, Germany) connected to a BX-51 micro-
scope (Olympus). 
Second series of tissue sections were stained 
with haematoxylin and eosin for evaluation of tu-
mour necrosis. These slides were examined under 
the microscope Olympus BX-51 and visual light 
images were recorded with a digital camera DP72 
CCD (Olympus). Digital images of haematoxylin 
and eosin stained tumour sections were analysed 
in blind fashion and percentage of necrosis was es-
timated by 4 independent observers.
Statistical analysis
SigmaPlot 11.0 (Systat Software Inc., San Jose, CA, 
USA) was used for statistical analysis. Normal dis-
tribution of the data was tested using Shapiro-Wilk 
test. All pairwise multiple comparisons for normal-
ly distributed data were tested with Holm-Sidak 
test after One Way ANOVA. All pairwise multiple 
comparisons for data that was not normally distrib-
uted were tested using Tukey test or Dunn’s test (if 
treatment group sizes were unequal) after Kruskal-
Wallis One-Way ANOVA on ranks. Differences 
were considered significant when p value was less 
than 0.05. 
Results
TNF-α does not potentiate CDDP 
cytotoxicity 
In vitro sensitivity of SA-1 cells to electrochemo-
therapy with or without TNF-α was determined 
by clonogenic assay (Figure 2). TNF-α in all the 
selected concentrations up to 2.5·105 U/mL did not 
exert any direct cytotoxic effect on SA-1 cells in 
vitro. Furthermore, no interaction of TNF-α with 
CDDP or electrochemotherapy was noticed at both 
concentrations of CDDP tested. 
Adjuvant TNF-α before or after ECT  
in vivo?
To determine if TNF-α can potentiate antitumor 
effectiveness of electrochemotherapy with intra-
Figure 2. Cell survival after electrochemotherapy with TNF-α 
at different doses. The surviving fraction of cells exposed to 
electrochemotherapy was normalized to electric pulses alone. 
Symbols represent median ± MAD. 
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venous CDDP injection in vivo, we evaluated the 
effect of intratumoural TNF-α injection before 
or after electrochemotherapy on tumour growth 
(Table 1). A relatively low CDDP dose of 4 mg/kg 
was selected in order to be able to demonstrate the 
possible interaction with adjuvant TNF-α therapy. 
Among all the combined modality groups only 
the adjuvant TNF-α therapy to electrochemother-
apy produced significant tumour growth delay 
compared to control tumours and resulted in tu-
mour cures. In these combined treatment groups, 
tumour doubling times were greater than the 
sum of tumour doubling times of single therapies 
(Table 1). Specifically, the treatment of tumours 
before the electrochemotherapy was significantly 
more effective (p<0.05) than treatment with TNF-α 
after electrochemotherapy, producing longer tu-
mour growth delay, and higher tumour curabil-
ity rate (36% vs. 27%, respectively) (Table 1). The 
single or combined therapies did not have toxic 
side effects or did not induce animal weight loss 
for more than 10% of the body weight (data not 
shown).
Platinum content in tumours after 
treatment
To determine whether TNF-α treatment affects 
CDDP uptake in tumours, platinum content in 
whole tumours was determined 24 h post treat-
ment. Significant differences in platinum concen-
tration in tumours were observed after different 
treatments (Figure 3). Tumour treatment with elec-
trochemotherapy alone or with TNF-α resulted in 
significantly higher platinum concentration in the 
whole tumours (p<0.05). Electrochemotherapy in-
creased platinum content in the tumours, as expect-
ed, approximately by factor of 2.19 Furthermore, 
in the TNF-α with the electrochemotherapy treat-
ment group, platinum content in tumours was fur-
ther significantly increased compared to tumours 
treated with either electrochemotherapy or TNF-α 
in combination with CDDP without EP. Overall 
2.2-fold increase in tumour platinum content was 
observed. The data do not prove the internalisation 
of the platinum in the cells of tumours, but rather 
indicate on the overall platinum content in the tu-
mours. 
Histological analysis
The effect on tumour blood vessels was demonstrat-
ed by immunohistochemical analysis of anti-CD31-
stained blood vessels in viable regions of tumours 
24 h after treatments (Figure 4). Differences were 
observed in tumours treated with either CDDP or 
electrochemotherapy in comparison to tumours 
treated with TNF-α in combination with CDDP or 
electrochemotherapy. A strong anti-CD31 staining 
was observed in tumours treated with either CDDP 
or electrochemotherapy, while anti-CD31 staining 
in tumours treated with TNF-α was much weaker. 
In tumours treated with CDDP alone, typical tu-
mour blood vessels network with thin vessels walls 
consisting only of endothelial cells was observed 
Table 1. Tumour doubling times and growth delay after different treatments. TNF-α 
was applied either before (TNF-α +) or after (TNF-α -) treatment
Treatment group n Doubling time  (mean ± SEM)
Growth delay 
(vs. control) Cures
Control 7 2.2 ± 0.1
EP 7 3.2 ± 0.4 1.0
CDDP 7 3.1 ± 0.2 0.9
TNF-α 7 2.9 ± 0.1 0.7
ECT 8 4.1 ± 0.9 1.9
TNF-α -5 min + EP 10 7.2 ± 0.4 5.0
TNF-α +5 min + EP 10 5.8 ± 0.5 3.6
TNF-α -2 min + CDDP 10 3.7 ± 0.4 1.5
TNF-α +8 min + CDDP 10 3.5 ± 0.3 1.3
TNF-α -5 min + ECT 11 23.7 ± 2.3*‡ 21.5 4 (36%)
TNF-α +5 min + ECT 11 15.4 ± 1.5* 13.2 3 (27%)
* = Significantly increased doubling time in comparison to other treatment groups; ‡ = Significantly 
increased doubling time in comparison to TNF- α +5 min + ECT. p<0.05
*
*
#
Figure 3. Platinum content in tumours 24 h after different 
treatments. Increased platinum uptake was observed after 
electrochemotherapy and exposure to TNF-α. Bars represent 
mean ± SEM. * p<0.05 vs. CDDP, # p<0.05 vs. CDDP, ECT and 
TNF+CDDP. 
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(Figure 4A). After electrochemotherapy, most of 
the blood vessels were narrowed indicating clearly 
seen vasoconstriction (Figure 4B). Number of func-
tional blood vessels was significantly reduced in 
tumours after treatment with TNF-α. In tumours 
treated with combination of TNF-α and CDDP, tu-
mour vessels were dilated, with stacked erythro-
cytes (Figure 4C). This effect was more pronounced 
after treatment with combination of TNF-α and 
electrochemotherapy, where only few large di-
lated blood vessels with mostly hyperaemic and 
occasionally damaged blood vessels and in some 
areas also extravasated erythrocytes were observed 
(Figure 4D).
Necrosis of tumour tissue was evaluated histo-
logically in all samples 24 h after different treat-
ments (Figure 5). Cisplatin treatment did not result 
in significantly increased necrosis compared with 
control untreated tumours.19 The degree of necro-
sis was significantly increased in tumours treated 
with adjuvant TNF-α and electrochemotherapy in 
comparison to tumours treated with CDDP, elec-
trochemotherapy or combination of TNF-α and 
CDDP. 
Is TNF-α interaction with 
electrochemotherapy CDDP dose 
dependent?
In the second part of the study, the effect of com-
bined TNF-α and electrochemotherapy with dif-
ferent CDDP doses (1-8 mg/kg) on tumour growth 
was evaluated. Based on the previous experiment, 
adjuvant TNF-α therapy was given before electro-
chemotherapy.
As predicted, electroporation significantly po-
tentiated CDDP effectiveness, which was CDDP 
dose dependent (Figure 6). Electrochemotherapy 
with the CDDP doses of 6 and 8 mg/kg produced 
significant tumour growth delay of 8.4 ± 0.8 and 
10.3 ± 0.8 days. The adjuvant intratumoural TNF-α 
therapy significantly potentiated the effectiveness 
of electrochemotherapy at all the CDDP doses 
used, also at the lowest CDDP dose of 1 mg/kg that 
had no effect in electrochemotherapy. Synergistic 
effect of combined treatment modality was ob-
served at lower CDDP doses (1 and 4 mg/kg), 
where tumour doubling time of combined treat-
ment modality was greater than the additive effect 
of single therapies. Addition of TNF-α to electro-
chemotherapy prolonged tumour doubling time 
for 5.5 days in comparison to electrochemotherapy 
treatment alone throughout the tested concentra-
tion range. This synergistic effect of the therapies is 
supported by the fact that only the tumours in com-
bined modality protocol were cured and tumours 
treated with electrochemotherapy alone were not. 
Namely, after combined treatment of TNF-α and 
electrochemotherapy with 6 mg/kg CDDP, 2 mice 
(9.5%) were cured, and after combined treatment 
of TNF-α and electrochemotherapy with 8 mg/kg 
CDDP, 1 mouse (4.3%) was cured.
Discussion
In the study, the antitumour effectiveness of TNF-α 
combined with electrochemotherapy with intrave-
nous CDDP was evaluated in murine fibrosarcoma 
tumour model. Adjuvant immunotherapy with 
TNF-α preceding electrochemotherapy, increased 
antitumor effectiveness of electrochemothera-
py with intravenous CDDP. Prolonged tumour 
growth and increased tumour curability were ob-
served after combined treatment with TNF-α and 
electrochemotherapy with intravenous CDDP. 
The underlying mechanism is most likely vascular 
targeted effect of TNF-α combined with its immu-
nomodulatory effect, as previously proposed for 
Figure 4. Vascular effect of different treatments. Anti-CD31 staining of tumour 
sections in tumours 24 h after different treatments at 40x magnification. (a) A typical 
tumour blood vessels network with thin vessels walls consisting only of endothelial 
cells was observed after CDDP alone (arrow). (b) After electrochemotherapy 
vasoconstriction of blood vessels was observed (arrow). (C) Dilated tumour vessels 
with stacked erythrocytes were observed after combination of TNF-α and CDDP 
(arrow). (D) After combination of TNF-α and electrochemotherapy only few large 
dilated blood vessels with mostly hyperaemic and occasionally damaged blood 
vessels were observed. (a) – CDDP; (b) – electrochemotherapy; (C) – TNF-α and 
CDDP; (D) – TNF-α and electrochemotherapy). Scale bar 100 µm. 
A B
C D
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combination with electrochemotherapy with bleo-
mycin.16
Electrochemotherapy gained clinical recognition 
in the treatment of cutaneous tumours or metasta-
ses as well as deep-seated tumours.2-4,6-11 Currently, 
bleomycin is the drug of choice for majority of the 
electrochemotherapy treatments, although CDDP 
is also in Standard Operating Procedures, but only 
if applied intratumoural. CDDP applied intrave-
nously has not been recognized to be sufficiently 
effective.1 However, this was based on a report 
where EP were applied on large tumours that were 
not expected to respond to systemic chemotherapy 
in metastatic melanoma patients.13 Due to the size 
of these treated tumours (the longest diameter of 
tumours mainly exceeded 3 cm) the response was 
not comparable to bleomycin data, where predom-
inantly tumours less than 3 cm in diameter were 
treated.20-23 Nevertheless, it is expected that with 
time CDDP will gain recognition, predominantly 
in such situations as in the first study13, or when its 
effectiveness could be potentiated with adjuvant 
treatment. 
Recently, it was demonstrated that tumours 
larger than 3 cm in size have lower response rate 
after single electrochemotherapy treatment than 
smaller ones.22,24,25 Furthermore, in preclinical stud-
ies, it was shown that electrochemotherapy with 
bleomycin induces immunological cell death16, 
providing additional rational for combination with 
immunotherapy. Therefore, one way to potenti-
ate electrochemotherapy effectiveness is adjuvant 
immunotherapy using different cytokines, such as 
interleukin 2 and 12, granulocyte-monocyte colony 
stimulating factor, and TNF-α.26-30 All these studies 
have provided evidence that electrochemotherapy 
with bleomycin can be potentiated with adjuvant 
immunotherapy, demonstrating increased tumour 
growth delay as well as tumour curability. It was 
already demonstrated that electrochemotherapy 
with bleomycin can be effectively potentiated in 
sarcoma model by TNF-α30, however, combination 
of electrochemotherapy with CDDP with adjuvant 
immunotherapy has not been tested yet. 
TNF-α is a well-known pro-inflammatory cy-
tokine with a wide range of biological functions, 
including an immunomodulatory role and anti-
vascular action.17,18 Due to its side effects, Its in-
travenous administration is not recommended31, 
therefore we decided to use intratumoural route 
and combined it with electrochemotherapy with 
intravenous CDDP administration. 
Our results demonstrated potentiation of antitu-
mour effectiveness of electrochemotherapy in com-
bination with TNF-α in vivo. A synergistic interac-
tion between TNF-α and electrochemotherapy with 
intravenous CDDP administration was observed. 
This synergistic interaction cannot be attributed to 
TNF-α cytotoxicity to tumour cells due to the lack 
of the effect in vitro. Contrary to early speculations 
of TNF-α cytotoxic action on malignant cells in ani-
mal tumour models, it is now accepted that TNF-α 
is weakly cytotoxic to malignant cells.32 Our in vitro 
results support this, as no cytotoxic effect of TNF-α 
Figure 5. Percentage of necrosis in tumours 24 h after different treatments. (a) 
Increased percentage of necrotic tumour area was observed 24 h after treatment 
with combination of TNF-α and electrochemotherapy. (B-E) Haematoxylin and 
eosin staining of tumour sections in tumours 24 h after different treatments at 4x 
magnification. (b) – CDDP; (C) – electrochemotherapy; (D) – TNF-α and CDDP; (e) 
– TNF-α and electrochemotherapy. Scale bar 1 mm. Bars represent mean ± SEM. * 
p<0.05 vs. CDDP, ECT, and TNF + CDDP. 
Figure 6. In vivo application of TNF-α and electrochemotherapy 
with different CDDP doses. Tumour doubling times after 
treatment with TNF-α and electrochemotherapy with 
different doses of CDDP were increased in comparison to 
electrochemotherapy alone. Symbols represent mean ± SEM. * 
p<0.05 vs. EP, ECT 1 mg/kg and ECT 4 mg/kg; # p<0.05 vs. TNF-α 
+ EP; § p<0.05 vs. TNF-α + EP and TNF-α + ECT 1 mg/kg; ‡ p<0.05 
vs. TNF-α + EP and TNF-α + ECT 1-4 mg/kg.
A B C
D E
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alone or in combination with electric pulses on SA-
1 fibrosarcoma cells was observed. Similarly, no 
cytotoxic effect of TNF-α in combination with EP 
for electrochemotherapy was observed in our pre-
vious study.30 Therefore, it is more likely that cell 
types other than tumour cells, such as endothelial 
cells or immune cells found in the tumour stroma 
are responsible for the observed antitumour effect. 
In vivo, two distinct and successive effects of 
TNF-α on tumour-associated vasculature are 
known. Firstly, TNF-α increases vascular endothe-
lium permeability, resulting in reduction of inter-
stitial fluid pressure and improved penetration of 
chemotherapeutic agents within the tumour tissue, 
and secondly, TNF-α causes tumour vessel de-
struction.33-36 The mechanism whereby these events 
occur involves rapid perturbation of cell-cell adhe-
sive junctions, leading to loss of intercellular adhe-
sion, and inhibition of αvβ3 integrin signalling in 
tumour-associated vessels.36 Specifically, it selec-
tively damages the integrity of tumour vasculature 
by disrupting VE-cadherin complexes and thus cre-
ates gaps between endothelial cells.37 In addition, 
the expression of TNF-α receptors is speculated to 
be up-regulated in tumour vessels in comparison 
to normal vessels, which makes tumour blood ves-
sels specific targets for TNF-α treatment.38 Binding 
of TNF-α to its receptors on endothelial cells trig-
gers apoptosis and leads to hyperpermeability of 
the tumour blood vessels, and extravasation of 
blood cells.38 In our study, anti-vascular action of 
TNF-α was confirmed by histological analysis of 
tumour sections. TNF-α treatment damaged ex-
isting blood vessels, resulting in weak anti-CD31 
staining. In addition, number of functional blood 
vessels was significantly reduced after expo-
sure to TNF-α. Blood vessels were dilated with 
stacked erythrocytes. This effect was even more 
pronounced after TNF-α combined with electro-
chemotherapy, where also extravasated erythro-
cytes were observed. In addition, overall platinum 
content in tumours was increased 24 h after treat-
ment with TNF-α compared to tumours treated 
with CDDP alone indicating facilitated uptake of 
CDDP in TNF-α treated tumours. This correlates 
well with other studies where improved penetra-
tion and increased uptake of anticancer drugs was 
observed in combination with TNF-α.39,40 
Taken together, our results indicate indirect 
antitumour action of adjuvant TNF-α in SA-1 fi-
brosarcoma tumours treated with ECT with low 
CDDP doses. This antitumour action of TNF-α is 
likely due to hyperpermeability of tumour blood 
vessels, leading also to increased accumulation of 
CDDP in the tumours. Based on these results, we 
speculate that the mechanism of action of adjuvant 
TNF-α in electrochemotherapy treated tumours is 
primarily through a vascular action. Nonetheless, 
especially at higher CDDP doses, at which tumour 
cures were obtained, involvement of activated 
immune response should be taken into account. 
Namely, in clinical settings, induction of inflam-
matory response after TNF-α based isolated limb 
perfusion was observed in the tumour tissue.36 
However, involvement of non-immunological an-
titumour mechanism of TNF-α is also supported 
by our previous study, where we showed antitu-
mour effect of TNF-α also in immunosuppressed 
mice.41 Indeed, in our study, we did not detect the 
significant infiltration of immune cells into the tu-
mours in histological section, most probably due 
to the early time of tumours excision after the 
therapy. Namely, the vascular effect of TNF-α is 
rapid, while immune adaptive response of the or-
ganisms needs the time to develop. Nevertheless, 
tumour curability after the combined treatment 
should be attributed to the involvement of adap-
tive immune system. We speculate that by replac-
ing the recombinant TNF-α with local TNF-α gene 
therapy, which would result in longer persistence 
of therapeutic TNF-α concentrations in organism, 
the immunological components of the synergistic 
effect would account for higher curability rate. 
In conclusion, adjuvant intratumoural TNF-α 
therapy synergistically contributes to electrochem-
otherapy with intravenous CDDP administration. 
Due to its potentiation at all doses of CDDP, the 
combined treatment is predicted to be effective also 
in less perfused areas of tumours, where the drug 
accumulation is not optimal, or in bigger tumours, 
where the effectiveness of electrochemotherapy 
with intravenous CDDP is not expected to be suf-
ficiently effective. Its synergistic effectiveness can 
be attributed to actions of TNF-α; vascular and also 
immunomodulatory, that could be further poten-
tiated by replacing the injection of recombinant 
TNF-α protein with application of gene therapy 
with TNF-α. 
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